Linagliptin/Empagliflozin

Tier C — Watch / trade

Boehringer Ingelheim

Originator

2015

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：DPP4, SGLT2

Brand：Glyxambi, Tradiance, Esgliteo

Indications (approved)：Cardiac and vascular disorders, Type 2 diabetes

Regional status

Approved

2015-01-30

Approved

2016-11-11

China

Japan

Approved

2018-09-21

Factories producing this API11

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

11 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Linagliptin/Empagliflozin?

Approved indications include: Cardiac and vascular disorders, Type 2 diabetes.

When does the Linagliptin/Empagliflozin patent expire?

No public expiry year is available for Linagliptin/Empagliflozin yet; this page updates once verified.

How do I get a quote for Linagliptin/Empagliflozin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29